Profile data is unavailable for this security.
About the company
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. The Company develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.
- Revenue in USD (TTM)0.00
- Net income in USD-17.69m
- Incorporated2020
- Employees9.00
- LocationTiziana Life Sciences Ltd3Rd Floor, 11-12 St. James's SquareLONDON SW1Y 4LBUnited KingdomGBR
- Phone+44 207 495 2379
- Websitehttps://www.tizianalifesciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Relmada Therapeutics Inc | 0.00 | -86.76m | 98.97m | 20.00 | -- | 1.61 | -- | -- | -2.88 | -2.88 | 0.00 | 2.04 | 0.00 | -- | -- | 0.00 | -89.88 | -- | -100.40 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
| MDxHealth SA | 80.74m | -40.80m | 100.48m | 300.00 | -- | -- | -- | 1.24 | -1.54 | -1.54 | 3.06 | -0.3229 | 0.5906 | 9.39 | 7.49 | 269,136.70 | -29.85 | -51.62 | -43.63 | -64.72 | 62.64 | 50.88 | -50.54 | -117.64 | 0.8252 | -1.74 | 1.18 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
| Werewolf Therapeutics Inc | 9.28m | -53.73m | 100.51m | 45.00 | -- | 0.9663 | -- | 10.83 | -1.35 | -1.35 | 0.236 | 2.38 | 0.0548 | -- | 2.48 | 197,510.60 | -31.70 | -- | -34.39 | -- | -- | -- | -578.80 | -- | -- | -- | 0.1948 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
| Rapt Therapeutics Inc | 0.00 | -120.43m | 100.87m | 122.00 | -- | 0.9236 | -- | -- | -3.12 | -3.12 | 0.00 | 3.13 | 0.00 | -- | -- | 0.00 | -69.23 | -46.30 | -75.81 | -49.97 | -- | -- | -- | -3,522.72 | -- | -- | 0.00 | -- | -100.00 | -- | -39.31 | -- | -20.31 | -- |
| Genelux Corp | 8.00k | -26.54m | 101.19m | 23.00 | -- | 2.65 | -- | 12,648.62 | -0.9704 | -0.9704 | 0.0003 | 1.11 | 0.0002 | -- | -- | 347.83 | -69.34 | -- | -84.43 | -- | -- | -- | -331,725.00 | -- | -- | -- | 0.00 | -- | -98.46 | -- | -443.44 | -- | -- | -- |
| Bioatla Inc | 0.00 | -104.56m | 101.51m | 65.00 | -- | 3.24 | -- | -- | -2.18 | -2.18 | 0.00 | 0.6491 | 0.00 | -- | -- | 0.00 | -84.23 | -48.72 | -106.06 | -57.35 | -- | -- | -- | -6,651.71 | -- | -- | 0.00 | -- | -- | -- | -15.95 | -- | -37.01 | -- |
| Renovaro Inc | 0.00 | -80.65m | 102.53m | 25.00 | -- | 0.7447 | -- | -- | -0.7942 | -0.7942 | 0.00 | 0.8513 | 0.00 | -- | -- | 0.00 | -72.84 | -39.86 | -89.56 | -42.11 | -- | -- | -- | -- | -- | -10.76 | 0.0182 | -- | -- | -- | -103.23 | -- | -37.12 | -- |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -17.69m | 102.91m | 9.00 | -- | 17.32 | -- | -- | -0.1726 | -0.1726 | 0.00 | 0.0537 | 0.00 | -- | -- | 0.00 | -91.52 | -58.16 | -138.98 | -75.36 | -- | -- | -- | -- | -- | -- | 0.0427 | -- | -- | -- | -14.90 | -- | -- | -- |
| CervoMed Inc | 9.65m | -5.04m | 103.50m | 8.00 | -- | 2.07 | -- | 10.72 | -0.4796 | -0.4796 | 1.55 | 6.06 | 0.2803 | -- | -- | 1,206,660.00 | -14.64 | -53.67 | -15.71 | -58.89 | -- | -- | -52.24 | -949.54 | -- | -- | 0.00 | -- | -- | -- | 86.07 | -- | -- | -- |
| Cue Biopharma Inc | 8.30m | -46.96m | 103.56m | 53.00 | -- | 3.87 | -- | 12.48 | -0.9743 | -0.9743 | 0.1718 | 0.4445 | 0.1437 | -- | 5.56 | 156,528.30 | -81.32 | -57.45 | -113.52 | -68.41 | -- | -- | -566.02 | -810.87 | -- | -- | 0.2242 | -- | 340.88 | 36.88 | 4.30 | -- | -- | -- |
| X4 Pharmaceuticals Inc | 563.00k | 17.63m | 104.05m | 93.00 | 7.21 | 1.10 | 5.76 | 184.81 | 0.0857 | 0.0857 | 0.0028 | 0.5616 | 0.0029 | -- | 0.6726 | 6,053.76 | 9.18 | -61.53 | 10.59 | -69.20 | 52.40 | -- | 3,131.79 | -13,288.93 | 6.04 | -- | 0.4427 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
| Milestone Pharmaceuticals Inc | 0.00 | -48.41m | 105.47m | 47.00 | -- | 3.30 | -- | -- | -1.01 | -1.01 | 0.00 | 0.6003 | 0.00 | -- | -- | 0.00 | -51.98 | -48.44 | -55.36 | -51.56 | -- | -- | -- | -1,267.25 | -- | -- | 0.6171 | -- | -80.00 | -- | -2.22 | -- | 86.23 | -- |
| Immunic Inc | 0.00 | -95.31m | 106.29m | 77.00 | -- | 1.67 | -- | -- | -1.51 | -1.51 | 0.00 | 0.7058 | 0.00 | -- | -- | 0.00 | -108.78 | -72.09 | -141.92 | -80.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.25 | -- | -10.97 | -- |
| Assembly Biosciences Inc | 21.48m | -45.61m | 106.48m | 65.00 | -- | 3.07 | -- | 4.96 | -9.32 | -9.32 | 4.28 | 5.47 | 0.2362 | -- | 125.62 | 330,476.90 | -50.15 | -39.69 | -69.22 | -44.03 | -- | -- | -212.33 | -409.24 | -- | -- | 0.00 | -- | -- | -13.51 | 34.23 | -- | -5.59 | -- |
| Annovis Bio Inc | 0.00 | -43.02m | 106.52m | 6.00 | -- | -- | -- | -- | -4.42 | -4.42 | 0.00 | -0.1494 | 0.00 | -- | -- | 0.00 | -308.78 | -106.31 | -395.89 | -124.71 | -- | -- | -- | -- | -- | -51.53 | -- | -- | -- | -- | -121.90 | -- | -- | -- |
| Adicet Bio Inc | 0.00 | -117.88m | 107.95m | 143.00 | -- | 0.5103 | -- | -- | -1.70 | -1.70 | 0.00 | 2.57 | 0.00 | -- | -- | 0.00 | -49.20 | -37.03 | -53.58 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
Data as of Nov 08 2024. Currency figures normalised to Tiziana Life Sciences Ltd's reporting currency: US Dollar USD
0.74%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Geode Capital Management LLCas of 30 Jun 2024 | 219.52k | 0.21% |
| HSBC Bank Plc (Broker)as of 30 Jun 2024 | 125.37k | 0.12% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 71.37k | 0.07% |
| Zhang Financial LLCas of 30 Sep 2024 | 69.39k | 0.07% |
| Ausdal Financial Partners, Inc.as of 30 Sep 2024 | 55.70k | 0.05% |
| UBS Securities LLCas of 30 Jun 2024 | 51.57k | 0.05% |
| EWA LLCas of 30 Jun 2024 | 51.17k | 0.05% |
| Barclays Bank Plc (Private Banking)as of 30 Jun 2024 | 47.50k | 0.05% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 2024 | 38.54k | 0.04% |
| CapFinancial Partners LLCas of 30 Jun 2024 | 34.60k | 0.03% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
